| abstract |
Compounds of formula (I) are inhibitors of HSP90 activity ex vivo or in vivo and are particularly used for cancer treatment:n n n n n n n n In which R 2 is a group of the formula-(Ar 1 ) m- (Alk 1 ) p- (Z) r- (Alk 2 ) s -Q, wherein Ar 1 is an optionally substituted aryl or heteroaryl group, Alk 1 and Alk 2 are optionally substituted divalent C 1 -C 3 alkylene or C 2 -C 3 alkenylene groups, m, p, r and s are each 0 or 1, and Z is -O-,- S-,-(C = O)-,-(C = S)-, -SO 2- , -C (= O) O-, -C (= O) NR A- , -C (= S) NR A- , -SO 2 NR A- , -NR A C (= 0)-, -NR A SO 2 -or -NR A- , where R A is hydrogen or C 1 -C 6 alkyl, and Q is Hydrogen or a substituted carbon ring or heterocyclic group; R 3 is hydrogen, optionally substituted or optionally substituted (C 1 -C 6 ) alkyl, aryl or heteroaryl group; R 4 is a carboxyl ester, carboxamide or sulfonamide group. |